Relevare Pharmaceuticals Presents Latest Clinical Trial Data on CNSB015 at Third International Congress on Neuropathic Pain in Athens, Greece

 

 

MELBOURNE, Australia and SAN FRANCISCO, May 28 /PRNewswire/ -- Relevare Pharmaceuticals Ltd. will present its recent Phase IIa proof-of-concept clinical trial data and extension study results for CNSB015 (flupirtine), its lead repositioned compound, at the Third International Congress on Neuropathic Pain on May 27 -30 in Athens, Greece.
 

Dr. Kate Cherry, MD, PhD, Head of the Neuropathy and Drug Toxicity Group at the Burnet Institute in Melbourne, Australia will share the results of the Company's Phase IIa trial, entitled, "Flupirtine as an adjunct to opioid analgesia in HIV neuropathy pain" during the Conference's Poster Session on Friday, May 28, 2010.
 

The results of the recently completed 12-month open-label extension study to be presented by Dr Cherry provide further evidence of the safety and efficacy of flupirtine. In particular, the data indicate clinically relevant improvements for the patients involved in the study in terms of both pain relief and quality of life (mean reductions in BPI Pain Severity and Pain Interference Indices of approximately 30%) when flupirtine is given as an adjunct to opioids.
 

Flupirtine is orally administered, and used in combination with opioids for the treatment of neuropathic pain. It works by opening potassium channels in the spinal cord and reducing responsiveness and sensitivity to pain signals. Flupirtine may also prevent and/or reverse the development of tolerance to opioid drugs, delivering long-term efficacy of flupirtine/opioid combination therapies without the need to increase dosage.
 

Mark Blumling, Managing Director of Relevare Pharmaceuticals said: "Flupirtine has been used safely as an analgesic in Germany for over 20 years, and we are pleased with the results of this extension study, which focused on the hard to treat area of painful HIV neuropathy."
 

The Alfred Hospital has guaranteed funding for the ongoing supply of flupirtine for all patients who completed the open-label study, under the TGA Special Access Scheme. Patients who completed the open-label study at St Vincent's Hospital are also continuing treatment with flupirtine via the Alfred Hospital.
 

"There is significant is demand for new treatment options among patients with neuropathic pain resulting from conditions such as HIV, cancer and diabetes. We look forward to commencing a 300 patient phase IIb/III trial later this year with patients in Europe and Australia who suffer from opioid resistant cancer pain," he said.
 

About Relevare Pharmaceuticals
 

Relevare Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercialising treatments for people experiencing moderate and severe pain that results from diseases such as cancer, diabetes and HIV.
 

Relevare Pharmaceuticals is in the later stages of development for its lead repositioned compound CNSB015 (flupirtine), which is used in combination with opioids for the treatment of neuropathic pain (defined as pain associated with a functional abnormality of the nervous system). Currently, there are no approved drugs in the United States, or in much of the world, for either of the Company's initial target markets - neuropathic cancer pain and painful HIV sensory neuropathy. This creates a compelling, multi-billion dollar market opportunity for the successful commercialisation of Relevare Pharmaceutical's lead product, CNSB015.
 

Source: Relevare Pharmaceuticals Ltd.

CONTACT: Anne Wickham, + 61 419 185 664, awickham@boxingclever.net.au,
for Relevare Pharmaceuticals Ltd.
 

Posted: June 2010

View comments

Hide
(web3)